Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation

Stroke

Volumn 42, Issue 6, 2011, Pages 1717-1721

  Jowett, Sue ^a   Bryan, Stirling ^b   Mant, Jonathan ^c   Fletcher, Kate ^a   Roalfe, Andrea ^a   Fitzmaurice, David ^a   Lip, Gregory Y H ^d   Hobbs, F D Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

aspirin; atrial fibrillation; economic evaluation; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 79958274668     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.600767     Document Type: Article

References (23)

1. Hobbs FDR, Fitzmaurice DA, Jowett S, Mant J, Murray E, Bryan S, Raftery J, Davies M, Lip GYH. A randomised controlled trial and costeffectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study Health Technology Assessment. 2005;9:1-90.
2. Mant J, Wade D, Winner S. Health care needs assessment: Stroke. In Stevens A, Raftery J, Mant J, Simpson S (eds). Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews-I Series II Edition. Abingdon, Radcliffe Medical Press Ltd; 2004: 141-244.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991:22;983-938.
4. Mant M, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E, on behalf of the BAFTA investigators and the Midland Research Practice Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007:370;493-503. (Pubitemid 47212371)
5. Mant JWF, Richards SH, Hobbs R, Fitzmaurice DA, Lip GYH, Murray ET, Banting M, Fletcher K, Rahman J, Allan T, Raftery J, Bryan S, the Midlands Research Consortium of General Practice. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population. BMC Cardiovasc Disord. 2003;3:9.
6. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995:274;1839-1845. (Pubitemid 26001259)
7. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000:355;956-962. (Pubitemid 30148260)
8. O'Brien C, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005:293;699-706. (Pubitemid 40216039)
9. EuroQol Group. EuroQol: a new facility for the measurement of healthrelated quality of life. Health Policy. 1990:16;199-208.
10. Dolan P. Modelling valuations for health states. Med Care. 1997:11; 1095-1108.
11. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999: 8:3-15. (Pubitemid 29222784)
12. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005:14;487-496. (Pubitemid 40723857)
13. Jowett SM, Bryan S, Murray E, McCahon D, Raftery J, Hobbs FDR, Fitzmaurice DA. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haem. 2006:134;632-639. (Pubitemid 44253607)
14. Department of Health. NHS Reference Costs 2006/07. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAnd Guidance/DH-082571 (accessed 28 September 2010).
15. Curtis L, Netten A. Unit Costs of Health and Social Care 2006. Personal Social Services Research Unit. http://www.pssru.ac.uk/uc/uc2006contents. htm. 2006. (accessed 28 September 2010).
16. HM Treasury. The Green Book. Appraisal and Evaluation in Central Government. The Stationery Office. http://www.hm-treasury.gov.uk/d/green-book- complete.pdf (accessed 28 September 2010).
17. Dorman P, Dennis MS, Sandercock P. Are the modified "simple questions" a valid and reliable measure of health related quality of life after stroke? J Neurol Neurosurg Psychiatry. 2000:69;487-493.
18. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003:21;43-50. (Pubitemid 36332383)
19. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes 3rd edition. Oxford, Oxford University Press, 2005.
20. Barber JA, Thompson SG. Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ. 1998: 317;1195-1200. (Pubitemid 28488509)
21. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marké L. Cost effectivness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992:305;1457-1460.
22. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996:156;1829-1836. (Pubitemid 26295228)
23. Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes. J Health Serv Res Policy. 2001:6;92-98. (Pubitemid 32410452)